Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioSpecifics Technologies, a biopharmaceutical company developing collagenase based products, has appointed Matthew Geller to its board of directors, increasing the board to seven members.
Subscribe to our email newsletter
Dr Geller brings to BioSpecifics extensive financial experience with biotechnology companies as he has served for over 15 years as a sell-side analyst and investment banker covering biotechnology companies.
Dr Geller will serve as the financial expert on the audit committee and will be an independent class 1 director.
Thomas Wegman, president of BioSpecifics Technologies, said: “We are very pleased that Dr Geller is joining our board. His financial and scientific acumen and extensive experience in the industry will be invaluable to our organization as our lead collagenase product Xiaflex moves through late-stage clinical trials and towards the marketplace.”